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Medline (Ovid MEDLINE(R) without Revisions 1996 to June Week 1 2016). Searched on 02/06/2016 
1. anti?bioti*.mp.  
2. antibiotic.mp. or exp Anti-Bacterial Agents/  
3. exp Anti-Bacterial Agents/ or exp Anti-Infective Agents/ or anti infective.mp.  
4. antimicrobial.mp.  
5. anti microbial.mp.  
6. (anti?biot* or anti?infect* or anti?bact* or anti?microb*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]  
7. 1 or 2 or 3 or 4 or 5 or 6  
8. randomized controlled trial.pt.  
9. controlled clinical trial.pt.  
10. randomized.ab.  
11. placebo.ab.  
12. clinical trials as topic.sh.  
13. randomly.ab.  
14. trial.ti.  
15. 8 or 9 or 10 or 11 or 12 or 13 or 14  
16. exp animals/ not humans.sh.  
17. 15 not 16  
18. exp Safety/ or exp Patient Safety/ or safety.mp.  
19. exp "Drug-Related Side Effects and Adverse Reactions"/ or drug reaction.mp. or exp Drug Hypersensitivity/  
20. side effect.mp.  
21. adverse effect.mp.  
22. toxicity.mp.  
23. exp Anaphylaxis/ or anaphylaxis.mp.  
24. adverse event.mp.   
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25. Product Surveillance, Postmarketing/ or pharmacovigilance.mp. or exp Adverse Drug Reaction Reporting Systems/ or exp Pharmacovigilance/ or Drug 
Monitoring/  
26. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25  
27. 7 and 17 and 27  
28. limit 27 to (yr="2000 - 2016" and "all child (0 to 18 years)")  
29. malaria.mp. or exp Malaria/ 
30. exp HIV/ or HIV.mp. 
31. exp Tuberculosis/  
32. 29 or 30 or 31  
33. 28 not 32 
 
CENTRAL (Issue 6 of 12, June 2016). Searched on 02/06/2016 
1. MeSH descriptor: [Anti-Bacterial Agents] explode all trees 
2. (anti* near (infect* or biotic* or bacter* or microb*)) 
3. MeSH descriptor: [Safety] explode all trees 
4. MeSH descriptor: [Drug Hypersensitivity] explode all trees 
5. MeSH descriptor: [Drug-Related Side Effects and Adverse Reactions] explode all trees 
6. "toxicity":ti,ab,kw (Word variations have been searched) 
7. "anaphylaxis":ti,ab,kw (Word variations have been searched) 
8. MeSH descriptor: [Anaphylaxis] explode all trees 
9. MeSH descriptor: [Pharmacovigilance] explode all trees 
10. "pharmacovigilance":ti,ab,kw (Word variations have been searched) 
11. "adverse drug event":ti,ab,kw (Word variations have been searched) 
12. 1 or 2 
13. 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 
14. 12 and 13 




Clinicaltrials.gov. Searched on 02/06/2016 
Ongoing trials 
(antibiotic OR antibacterial OR antiinfective OR antimicrobial ) AND (safety OR drug hypersensitivity OR adverse reaction OR side effects OR hypersensitivity 
OR toxicity OR pharmacovigilance OR anaphylaxis ) AND EXACT ( "Recruiting" OR "Not yet recruiting" OR "Available" ) [OVERALL-STATUS] AND EXACT 
"Interventional" [STUDY-TYPES] AND EXACT Child [AGE-GROUP] AND ( "01/01/2000" : "06/02/2016" ) [FIRST-RECEIVED-DATE] 
Closed in the last 5 years 
(antibiotic OR antibacterial OR antiinfective OR antimicrobial ) AND (safety OR drug hypersensitivity OR adverse reaction OR side effects OR hypersensitivity 
OR toxicity OR pharmacovigilance OR anaphylaxis ) AND EXACT NOT ( "Recruiting" OR "Not yet recruiting" OR "Available" ) [OVERALL-STATUS] AND EXACT 
"Interventional" [STUDY-TYPES] AND EXACT Child [AGE-GROUP] AND ( "01/01/2011" : "06/02/2016" ) [FIRST-RECEIVED-DATE] 
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no Secondary Neonatal Sepsis 
Open label RCT 1:1 to 
• Amikacin OD 
• Amikacin BID 
30 Neonates 44 
Adler,  
2000 [2] 
Europe, South Africa and 
Australia 
nr yes Secondary URTI 
Open label RCT 1:1:1 to  
• Cefdinir OD 
• Cefdinir BID 
• Amoxicillin 
752 6 m - 12 y 67 
Afrinest,  
2015 [3] 
Democratic Republic of 




no Primary Unspecified BI 
Open label RCT 1:1 to 
• Procaine penicillin OD 
• Gentamicin OD & Amoxicillin BID 
2,196 0 - 59 d 80 
Afrinest,  
2015 [4] 
Democratic Republic of 




no Primary Unspecified BI 
Open label RCT 1:1:1:1 to 
• Gentamicin OD (7 days) + Procaine penicillin OD (7 
days) 
• Gentamicin OD (7 days) + Amoxicillin BID (7 days) 
• Gentamicin OD (7 days) + Procaine penicillin OD (2 
days) + Amoxicillin 5 days 
• Gentamicin OD (2 days) & Amoxicillin BID (2 days) + 
Amoxicillin BID (5 days) 






yes Secondary URTI 
Double blind RCT 1:1 to 
• Amoxicillin BID 
• Amoxicillin TID 
516 2 - 12 y 78 
Arguedas,  
2005 [6] 
Chile, US, Costa 
Rica and Finland 
09/2002-
07/2003 
yes Secondary URTI 
Double blind RCT 1:1 to 
• Azithromycin OD 
• Amoxicillin BID (High dose) 
306 6 – 30 m 78 
Arguedas,  
2009 [7] 
Colombia, USA, Slovenia, 
Chile, Peru, Spain, Romania, 







UTI, SSTI, LRTI 
Double blind RCT 3:1 to 
• Ertapenem OD or BID 
• Ceftriaxone OD or BID 









yes Secondary URTI 
Double blind RCT 1:1 to 
• Azithromycin ER OD (1 day) 
• Amoxicillin/clavulanate BID (10 days) 
902 3 - 48 m 56 
Arrieta,  
2003 [9] 
US, Latin American 
03/2001-
03/2002 
yes Secondary URTI 
Double blind RCT 1:1 to 
• Azithromycin OD (3 days, high-dose) 
• Amoxicillin/clavulanate BID (10 days) 
300 6 m-6 y 78 
Balatsouras,  
2005 [10] 
Greece (3 years) no Secondary URTI 
Open label RCT 1:1 to 
• Loracarbef BID (Low dose) 
• Loracarbef BID (High dose) 






yes Primary Unspecified BI 
Open label RCT 1:1:1 to 
• Procaine benzylpenicillin & gentamicin OD (7 days) 
• Gentamicin OD & Amoxicillin BID (7 days) 






no Secondary GII 
Open label RCT 2:3 to  
• Amoxicillin & Clarithromycin & Lansoprazole (14 
days) 
• Amoxicillin & Lansoprazole (5 days) + 
Clarithromycin & Ornidazole & Lansoprazole (5 days) 






no Secondary GII 
Open label RCT 1:1 to 
• Azithromycin OD (7 days) 
• Cefixime BID (14 days) 






yes Secondary URTI 
Double blind RCT 1:1:1 to 
• Cefdinir OD 
• Cefdinir BID 






yes Secondary URTI 
Double blind, phase 4 RCT 1:1 to 
• Cefdinir BID 
• Amoxicillin/Clavulanate BID (high dose) 






no Secondary URTI 
Open label RCT 1:1 to 
• Ceftibuten OD (5 days) 
• Azithromycin OD (3 days) 





Argentina, Brazil, Chile, Costa 




yes Secondary LRTI 
Open label RCT 3:1 to 
• Levofloxacin BID 
• Comparator: 
- 6 months-5 years: Amoxicillin/ clavulanate BID or 
Ceftriaxone 
- 5-16 years: Clarithromycine or Ceftriaxone &  
erythromycin lactobionate q6h or clarithromycin BID 






no Secondary UTI 
Open label RCT 1:1 to 
• Gentamicin OD 
• Gentamicin TID 






no Secondary Unspecified BI 
Open label RCT 1:1 to 
• Clarithromycin BID (7 days) 
• Chloramphenicol q6h (7 days) 






no Secondary Unspecified BI 
Open label RCT 1:1 to 
• Clarithromycin BID (7 days) 
• Azithromycin OD (3 days) 






no Secondary GII 
Open label RCT 1:1 to 
• Azitromycin OD (3 days) 
• Comparator: 
- <8 years: IV chloramfenicol q6h; 
- > 8 years: Doxycycline BID (>5 days) 






no Primary UTI 
Open label RCT 1:1 to 
• Gentamicin OD 
• Gentamicin TID 






no Secondary Unspecified BI 
Open label RCT 1:1 to 
• Gentamicin BID 
• Gentamicin OD 






yes Secondary Other BI 
Double blind RCT 1:1:1 to 
• Azithromycin topical (2 days) 
• Azithromycin topical (3 days) 
• Azithromycin OD (3 days) 






yes Secondary URTI 
Double blind RCT, 1:1:1 to 
• Azithromycin OD (3 days) 
• Azithromycin OD High dose (3 days) 





Argentina, Brazil, Costa Rica, 
India, Kenya, Mexico, 




yes Secondary URTI 
Single blind RCT 1:1 to 
• Amoxycillin/clavulanate BID (7 or 10 days) 
• Amoxycillin/clavulanate TID (7 or 10 days) 






no Secondary Unspecified BI 
Double blind RCT 1:1 to 
• Vancomycin loading dose + Vancomycin standard 
dose TID 
• Vancomicin standard dose TID 







no Primary LRTI 
Open label, phase 3 RCT 2:1 to 
• Linezolid TID 
• Vancomycin q6h or OD 






no Secondary Sepsis 
Open label RCT 1:1 to 
• Gentamicin OD 
• Gentamicin MD (Multi-dose) 
297 0 - 3 m 67 
Eppes,  
2002 [30] 
US 1997–1999 no Secondary Other BI 
Open label RCT 1:1:1 to 
• Cefuroxime axetil Low dose & Amoxicillin 
• Cefuroxime axetil High dose &Amoxicillin 






yes Secondary URTI 
Single blind RCT 1:1 to 
• Cefaclor BID (5 days) 
• Amoxicillin TID (10 days) 






yes Secondary LRTI 
Double blind RCT 1:1 to 
• Azithromycin OD (3 days) 
• Amoxicillin/clavulanate TID (10 days) 
110 3 m - 12 y 89 
Haczyński,  
2003 [33] 
Poland nr no Secondary URTI 
Double blind RCT 1:1 to 
• Cefaclor BID (10 days) 
• Amoxicillin/clavulanate TID (10 days) 
97 2 - 12 y 56 
Jantaush,  
2003 [34] 




no Secondary LRTI, Sepsis 
Open label, phase 3 RCT 2:1 to 
• Linezolid TID 
• Vancomycin q6h or OD 
151 0 - 12 y 78 
Kafetzis,  
2000 [35] 
Greece nr yes Secondary UTI 
Open label RCT 2:1 to 
• Isepamicin BID (10–14 days) 
• Amikacin BID (10–14 days) 








no Secondary URTI 
Open label RCT 1:1:1 to  
• Penicillin V TID (10 days) 
• Clarithromycin BID (10 days) 
265 3 - 14 y 67 
Kaplan,  
2003 [37] 
US, Latin America 
02/2001-
12/2001 
yes Secondary Unspecified BI 
Open label RCT 2:1 to 
• Linezolid TID 
• Vancomycin q6h or OD 
312 0 - 12 y 100 
Khan,  
2005 [38] 
Bangladesh nr no Secondary LRTI, GII 
Open label RCT 1:1 to 
• Gentamicin OD & Ceftriaxone OD 
• Gentamicin TID & Ceftriaxone OD 
310 6 m - 5 y 67 
Langley,  
2004 [39] 
Canada, US 1995-1998 yes Secondary URTI 
Open label RCT 1:1 to 
• Azithromycin OD (5 days) 
• Erythromicyn TID (10 days) 






yes Secondary URTI, LRTI 
Single blind RCT 1:1 to 
• Clarithromycin BID (7 days) 
• Erythromicyn TID (14 days) 
153 1 m - 16 y 89 
Lee,  
2008 [41] 
Taiwan nr no Secondary LRTI 
Open label RCT 1:1 to 
• Clarithromycin BID (10 days) 
• Erytromycin q6h (10 days) 






yes Secondary UTI 
Open label RCT 2:1 to 
• Ceftibuten OD (10 days) 
• TMP-SMX BID (10 days) 






no Secondary URTI 
Double blind, phase 3 RCT 1:1 to 
• Clarithromycin BID (10 days) 
• Penicillin V TID 






no Secondary Other BI 
Open label RCT 1:1 to 
• Clarithromycin BID (14 days) 
• Amoxicillin TID (14 days) 
130 0 - 15 y 89 
Noel,  
2008 [45] 
Argentina, Brazil, Chile, Costa 
Rica, Panama, US 
10/2002-
05/2005 
yes Secondary URTI 
Double blind RCT 1:1 to 
• Levofloxacin BID (10 days) 
• Amoxicillin/Clavulanate BID (10 days) 






yes Secondary LRTI 
Open label RCT 1:1 to 
• Cefotazime-sulbactam TID (7 days) 
• Amoxicillin/clavulanic TID (7 Days) 








no Primary GII 
Double blind RCT 1:1 to 
• Amikacin TID & Clindamycin q6h 
• Amikacin OD & Clindamycin q6h 
100 2 - 12 y 78 
Pichichero,  
2000 [48] 
US, Canada nr no Secondary URTI 
Double blind RCT  
A- 1:1:1 to 
• Cefdinir OD (10 days) 
• Cefdinir BID (10 days) 
• Penicillin V q6h (10 days) 
B- 1:1 to  
• Cefdinir BID (5 days) 
• Penicillin V q6h (10 days) 
1,273 6 m - 12 y 67 
Poachanukoon,  
2008 [49] 
Thailand nr no Secondary URTI 
Double blind RCT 1:1 to 
• Cefditoren pivoxil BID (14 days) 
• Amoxicillin/Clavulanate BID (14 days) 






no Secondary URTI 
Open label RCT 1:1 to 
• Josamycin BID (5 days) 
• Penicillin TID (10 days) 
324 3 - 12 y 56 
Saez-Llorens,  
2002 [51] 
US, Latin America, 




no Secondary CNS infection 
Open label RCT 1:1 to 
• Alatrofloxacin BID 
• Ceftriaxone OD +/- Vancomycin q6h 






no Secondary URTI 
Open label RCT 1:1:1 to 
• Cefcapene–pivoxil TID (5 or 10 days) 
• Amoxicillin TID (10 days) 






no Secondary LRTI 
Open label RCT 1:1 to 
• Cefepime BID 
• Ceftazidime TID 
30 0 – 12 m 33 
Sher,  
2005 [54] 
Costa Rica, US 
03/2001-
06/2002 
no Secondary URTI 
Double blind RCT 1:1 to 
• Gatifloxacin OD (10 days) 
• Amoxicillin/Clavulanate BID (10 days) 






no Secondary Unspecified BI 
Open label RCT 1:1 to 
• Gentamicin OD 
• Gentamicin BID or TID 





The Netherlands nr no Primary Unspecified BI 
Open label RCT 1:1 to 
• Gentamicin OD 
• Gentamicin multiple daily 







no Primary Neonatal Sepsis 
Double blind RCT 1:1 to 
• Amikacin OD & Ampicillin 
• Amikacin BID & Ampicillin 






no Secondary URTI 
Open label RCT 1:1 to 
• Amikacin OD 
• Amikacin BID 
109 3 m- 6 y 67 
Wible,  
2003 [59] 
US, Canada, Mexico, 




yes Secondary SSTI 
Double blind RCT 1:1 to 
• Linezolid BID 
• Cefadroxil BID 
494 5 - 17 y 78 
Yellin,  
2007 [60] 
US, Mexico, Brazil 
03/2002-
01/2004 
no Primary GII, other BI 
Open label RCT 3:1 to 
• Ertapenem BID  
• Ticarcillin/clavulanate q6h or q4h 
105 2 - 17 y 78 
Yogev,  
2003 [61] 
US, Mexico, South America 
02/2001-
12/2001 
no Secondary SSTI 
Open label RCT 2:1 to 
• Linezolid BID 
• Vancomycin q6h or OD 
119 0 - 12 y 78 
Zimbasa 
Dysentery 
Study Group,  
2002 [62] 




yes Secondary GII 
Double blind RCT 1:1 to 
• Ciprofloxacin BID (3 days) + placebo 
• Ciprofloxacin BID (5 days) 
252 12 m - 11 y 67 
NCT01400867 
[63] 
US, Argentina, Chile, Georgia, 
Latvia, Lithuania, Poland, 
Romania, South Africa, Spain 
12/2011-
07/2014 
yes Primary Other BI 
Single blind, phase 2, phase 3 RCT 
• Ceftaroline fosamil 
• Vancomycin +/- Aztreonam or Cefazolin +/- 
Aztreonam 
• Cephalexin or Clindamycin or Linezolid 
163 2 m - 17 y na 
NCT01530763 
[64] 
US, Argentina, Bulgaria, 
Georgia, Greece, Hungary, 
Poland, Spain, Ukraine 
09/2012-
07/2014 
yes Primary Other BI, LRTI 
Single blind, phase 2, phase 3 RCT  
• Ceftaroline fosamil 
• Amoxicillin/clavulanate 
161 2 m - 18 y na 
NCT01551394 
[65] 




yes Secondary Sepsis 
Open label RCT to 
• Meropenem (11±3 days) 
• Ampicillin/Gentamicin or Cefotaxime/Gentamicin 









yes Primary Other BI, LRTI 
Single blind, phase 4 RCT  
• Ceftaroline fosamil 
• Ceftriaxone & Vancomycin 






no Secondary LRTI 
Double blind, phase 4 RCT  
• Amoxicillin TID (5 days) 
• Amoxicillin TID (10 days) 
60 1 - 10 y na 
NCT01728376 
[68] 
Argentina, Australia, Brazil, 
Chile, Colombia, Greece, 
Guatemala, Hungary, Israel, 
Italy, Malaysia, Panama, 
Romania, Spain, Taiwan, 
Thailand, Ukraine, US 
11/2012-
01/2016 
yes Primary Sepsis 
Open label, phase 4 RCT  
• Daptomycin OD 
• SOC: Vancomycin, Semi-synthetic penicillin, First-
generation cephalosporins, Clindamycin 
82 1 - 17 y na 
NCT01922011 
[69] 
Argentina, Australia, Brazil, 
Bulgaria, Chile, Colombia, 
Estonia, France, Georgia, 
Germany, Greece, 
Guatemala, Hungary, Israel, 
Italy, Korea, Republic of, 
Latvia, Malaysia, Moldova, 
Republic of, New Zealand, 
Panama, Peru, Romania, 
Russian Federation, Serbia, 
South Africa, Spain, Turkey, 
Ukraine, UK, US 
09/2013-
ongoing 
yes Secondary Other BI 
Double blind RCT to 
• Daptomycin OD 
• Vancomycin q6h, or nafcillin q6h 






no Secondary GII 
Double blind RCT to 
• Ampicillin & Metronidazole & Gentamicin 
• Ampicillin & Gentamicin & Clindamycin 
• Gentamicin and Piperacillin- tazobactam   
• Standard of care antibiotics and Metronidazole 
• Metronidazole & clindamycin or peracillin-
tazobactam 






no Secondary LRTI 
Double blind, phase 4 RCT  
• Amoxicillin/Clavulanate BID (10 days) 
• Amoxicillin/Clavulanate BID (3 days) 





US, Argentina, Bulgaria, 
Chile, Czech Republic, 
Georgia, Germany, Latvia, 
Lithuania, Panama, Poland, 
Slovenia, South Africa, Spain 
03/2015-
ongoing 
yes Primary SSTI 
Single blind, RCT to 
• Tedizolid Phophate (6 days) 
• Antibiotic comparator 










Single blind, RCT to 
• Ceftriaxone 
• Flucloxacillin 






no Secondary LRTI 
Double blind RCT  
• Amoxicillin TID (5 days) 
• Amoxicillin TID (10 days) 
270 6 m - 10 y na 
NCT02475733 
[75] 
Argentina, Chile, Czech 
Republic, Greece, Hungary, 
Poland, Romania, Russia, 
Spain, Taiwan, Turkey, US 
05/2015-
ongoing 
yes Primary GII 
Single blind, phase 2 RCT 3:1 to 
• Ceftazidime -avibactam TID & metronidazole TID 
• Meropenem TID 
102 3 m - 18 y na 
NCT02497781 
[76] 
Czech Republic, Greece, 
Hungary, Poland, Romania, 




yes Primary UTI 
Single blind, phase 2 RCT 3:1 to 
• Ceftazidime-avibactam TID 
• Cefepime 






no Secondary Neonatal Sepsis 
Open label, phase 3 RCT  
• Meropenem TID (infused over 4 hours) 
• Meropenem TID (infused over 30 minutes) 






no Secondary URTI 
Double blind, placebo controlled RCT to 
• Amoxicillin-clavulanate (10 days) 
• Placebo 






yes Primary LRTI 
Open label, phase 2, phase 3 RCT  
• Solithromycin 
• SOC (intravenous ceftriaxone, ampicillin, and 
amoxicillin and oral amoxicillin and amoxicillin-
clavulanic acid) 








no Secondary GII 
Open label RCT to 
• Proton Pump Inhibitor & two antibiotics 
(Amoxicillin BID, Clarithromycin BID, Metronidazole 
BID) 
• Omeprazole BID & Amoxicillin BID & Clarithromycin 
BID 






no Secondary LRTI 
Double blind, placebo controlled RCT to 
• Amoxicillin-clavulanic Acid BID (8 days) 
• Placebo 
314 3 m - 5 y na 
NCT02790996 
[82] 






no Secondary Sepsis 
Open label RCT to 
• Vancomycin (Optimised Regimen) 
• Vancomycin (Standard Regimen) 








no Secondary GII 
Open label, RCT to 
• Piperacillin tazobactam TID 
• Appendectomy 
226 5 - 16 y na 
 
aproportion of items of the CONSORT 2004 on safety quality reporting [Ref] checklist that were adequately reported. UTI: Urinary tract infections, LRTI: Low Respiratory Tract 
Infection, URTI: Upper Respiratory Tract Infection, SSTI: Skin and Soft Tissue Infection, GI: Gastrointestinal Infection, BI: Bacterial Infection, na: not applicable 
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[N = 27,693] 
Number of 
trials (%) 
[N = 83] 
Penicillins 11,408 (41.2) 23 (27.7) 
Aminoglycosides 9,852 (35.6) 15 (18.1) 
Cephalosporins 4,014 (14.5) 25 (30.1) 
Penicillins and β-lactamase inhibitor 3,617 (13.1) 18 (21.7) 
Macrolides 3,292 (11.9) 21 (25.3) 
Fluoroquinolones 1,920 (6.9) 5 (6.0) 
Lincosamides 1,429 (5.2) 3 (3.6) 
Oxazolidinone 764 (2.8) 6 (7.2) 
Carbapenems 646 (2.3) 5 (6.0) 
Glycopeptides 585 (2.1) 7 (8.4) 
Sulfonamides and trimethoprim 152 (0.5) 1 (1.2) 
Imidazole derivates 133 (0.5) 2 (2.4) 
Lipopeptides 113 (0.4) 2 (2.4) 
Cephalosporins and β-lactamase inhibitor 50 (0.2) 1 (1.2) 











Sum of specific 
AEs 
Discontinuation 


















Penicillins 3,019 333 205 49 7 3 0 145 6 0 22 0 6 16 
Aminoglycosides 1,308 129 90 nr 0 75 6 0 9 0 0 0 0 0 
Cephalosporins 2,462 507 470 53 10 0 0 316 11 56 52 0 6 19 
Macrolides 2,931 802 640 34 34 0 0 511 0 3 79 0 0 13 
Penicillins +  
β-lactamase inhib 
2,566 1,394 1325 50 84 0 4 758 0 175 281 22 1 0 
Fluoroquinolones 1,920 1,304 916 44 89 0 0 388 0 202 119 56 0 62 
Carbapenems 385 122 111 6 0 0 0 27 0 0 0 0 42 42 
Linezolid 683 398 357 10 9 0 0 81 20 25 9 0 2 215 
Glycopeptides 265 192 181 8 48 5 0 23 1 0 21 0 0 84 
Sulfonamides + 
trimethoprim 
152 7 7 4 2 0 0 4 0 0 1 0 0 0 
Amphenicols 25 1 1 0 0 0 0 1 0 0 0 0 0 0 
Total 15,716 5,189 4,308 258 283 83 10 2,254 47 461 584 78 57 451 
 
*Population in which this parameter was evaluated; aincluding fever, anaphylaxis and Red Man Syndrome. Patients on combination of Aminoglycosides/Penicillin were included in 
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